Literature DB >> 17359977

A novel ROCK inhibitor, Y-39983, promotes regeneration of crushed axons of retinal ganglion cells into the optic nerve of adult cats.

Hiroe Sagawa1, Hiroko Terasaki, Makoto Nakamura, Masahiro Ichikawa, Takayuki Yata, Yoshihito Tokita, Masami Watanabe.   

Abstract

We investigated the effect of a novel ROCK inhibitor, Y-39983, on neurite regeneration in vitro and axonal regeneration in the crushed cat optic nerve in vivo. To determine the effective dose for neurite regeneration, retinal pieces were cultured with ROCK inhibitors, Y-39983 or Y-27632, a well-characterized ROCK inhibitor, and the number and length of TUJ-1-positive neurites were evaluated. The greatest number of neurites protruded at a dose of 3-10 microM Y-39983 and at a dose of 10-100 microM Y-27632, respectively. The neurite number at maximum effect of Y-39983 was greater than that of Y-27632. No significant difference was observed between values of neurite length with the inhibitors. Based on this finding, we examined the effect of Y-39983 on axonal regeneration in the crushed optic nerve in vivo. Immediately after crushing the left optic nerve, Y-39983 was injected into the vitreous and the crushed site. An injection of 10 microM Y-39983 induced the crushed axons to regenerate and pass over the crush site. In contrast, very few axons passed beyond the crush site in the optic nerve with phosphate-buffered saline injection. The second injection of 10 microM Y-39983 on day 7 doubled the number of regenerated axons, suggesting that new axons may have entered into the optic nerve after day 7 and that a continuous supply of the drug may make more axons to regenerate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359977     DOI: 10.1016/j.expneurol.2007.02.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  20 in total

1.  Regeneration of optic nerve fibers with unoprostone, a prostaglandin-related antiglaucoma drug, in adult cats.

Authors:  Hiroe Sagawa; Hiroko Terasaki; Keiko Nakanishi; Yoshihito Tokita; Masami Watanabe
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

Review 2.  Rho kinase inhibitors-a review on the physiology and clinical use in Ophthalmology.

Authors:  Nuno Moura-Coelho; Joana Tavares Ferreira; Carolina Pereira Bruxelas; Marco Dutra-Medeiros; João Paulo Cunha; Rita Pinto Proença
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-03-07       Impact factor: 3.117

Review 3.  Impact of the clinical use of ROCK inhibitor on the pathogenesis and treatment of glaucoma.

Authors:  Megumi Honjo; Hidenobu Tanihara
Journal:  Jpn J Ophthalmol       Date:  2018-02-14       Impact factor: 2.447

Review 4.  Role of the Rho GTPase/Rho kinase signaling pathway in pathogenesis and treatment of glaucoma: Bench to bedside research.

Authors:  Ponugoti Vasantha Rao; Padmanabhan P Pattabiraman; Casey Kopczynski
Journal:  Exp Eye Res       Date:  2016-09-01       Impact factor: 3.467

5.  Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage.

Authors:  Hai-Bo Tan; Yi-Sheng Zhong; Yu Cheng; Xi Shen
Journal:  Int J Ophthalmol       Date:  2011-12-18       Impact factor: 1.779

Review 6.  Approaches of targeting Rho GTPases in cancer drug discovery.

Authors:  Yuan Lin; Yi Zheng
Journal:  Expert Opin Drug Discov       Date:  2015-06-18       Impact factor: 6.098

7.  Intravitreal delivery of human NgR-Fc decoy protein regenerates axons after optic nerve crush and protects ganglion cells in glaucoma models.

Authors:  Xingxing Wang; Jun Lin; Alexander Arzeno; Jin Young Choi; Juliann Boccio; Eric Frieden; Ajay Bhargava; George Maynard; James C Tsai; Stephen M Strittmatter
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-02-05       Impact factor: 4.799

Review 8.  Status of Rho kinase inhibitors in glaucoma therapeutics-an overview.

Authors:  Bhawesh Chandra Saha; Rashmi Kumari; Rakhi Kushumesh; Anita Ambasta; Bibhuti Prasanna Sinha
Journal:  Int Ophthalmol       Date:  2021-08-27       Impact factor: 2.031

Review 9.  Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.

Authors:  Angelo P Tanna; Mark Johnson
Journal:  Ophthalmology       Date:  2018-07-12       Impact factor: 12.079

10.  The therapeutic effects of Rho-ROCK inhibitors on CNS disorders.

Authors:  Takekazu Kubo; Atsushi Yamaguchi; Nobuyoshi Iwata; Toshihide Yamashita
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.